Palvella Therapeutics announced the appointment of Matthew Korenberg as CFO, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Korenberg joins Palvella from Ligand Pharmaceuticals Inc. (LGND), where he served as President and COO since 2022 and CFO from 2015 to 2022. In July 2024, Palvella and Pieris Pharmaceuticals, Inc. (PIRS) announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential